Leveraging Human Genetics to Estimate Clinical Risk Reductions Achievable by Inhibiting Factor XI

Coagulation factor XI (FXI) is a novel target for antithrombotic therapy addressed by various therapeutic modalities currently in clinical development. The expected magnitude of thrombotic event reduction mediated by targeting FXI is unclear. METHODS—: We analyzed the association of 2 common genetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Georgi, Benjamin, Mielke, Johanna, Chaffin, Mark, Khera, Amit V., Gelis, Lian, Mundl, Hardi, van Giezen, J.J.J., Ellinor, Patrick, Kathiresan, Sekar, Ziegelbauer, Karl, Freitag, Daniel F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824502/
https://www.ncbi.nlm.nih.gov/pubmed/31558144
http://dx.doi.org/10.1161/STROKEAHA.119.026545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824502/
https://www.ncbi.nlm.nih.gov/pubmed/31558144
http://dx.doi.org/10.1161/STROKEAHA.119.026545

Ejemplares similares